Nanogroup S.A.

Activities of holding companies

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2016-12-02
Share capital
42,628,988.00 PLN
Activity description

NanoGroup SA is building a biotechnology group and developing projects in nanotechnology for medicine. Its projects include NanOX Recovery Box, NanOX 4 Kidney, AUX-001, and a pipeline with dextran conjugates and aptamers. The company also lists development milestones such as non-GLP studies, GMP batch production, and CE certification.

Registered address
ul. Rakowiecka 36, 02-532 Warszawa, Poland
Phone
Social media
Electronic delivery address
AE:PL-22876-83677-EBSWU-17

Financials

Revenue history (in k)

Filing timeliness

2 of 6 financial statements were filed late (the longest delay 45 days for 2021). All were audited by a statutory auditor.

  • 202514/07/2026
  • 202414/07/2025
  • 202305/08/2024
  • 202211/07/2023
  • 202129/08/2022
  • 202002/07/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Stock quotes

PLN 2.03
-0.04 (-1.70%)
2.022.042.062.0310:0012:0014:0016:00
Open
PLN 2.03
High
PLN 2.07
Low
PLN 2.02
Volume
85.1K
Avg. vol.
59.1K
Market cap
PLN 86.32M
P/E ratio
–
EPS
-PLN 0.36
Shares outstanding
42.63M
52-week
PLN 1.98 – 2.30
Dividend yield
–
Dividend
–
Ex dividend date
–
Exchange
GPW Main Market

Quarterly results

PeriodRevenueEBITNet profit
Q3 2026USD -33.77kUSD -1.36mUSD -1.33m
Q2 2026USD 33.77kUSD -1.19mUSD -1.16m
Q1 2026USD -1.89kUSD -613.99kUSD -604.27k
Q4 2025USD 1.76kUSD -972.12kUSD -963.84k

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2024.

Industry · Activities of holding companies172 / 899
Top 19%
Top 19%
Voivodeship · Mazowieckie36,787 / 142,204
Top 26%
Country · Poland134,882 / 496,474
Top 27%

Results vs industry

Revenue
This companyUSD 843.10kMedianUSD 53.72kAverageUSD 6.34m
Net profit
This companyUSD -478.08kMedianUSD 629.82AverageUSD 951.33k
Operating costs
This companyUSD 870.30kMedianUSD 13.83kAverageUSD 4.62m
Assets
This companyUSD 10.54mMedianUSD 896.80kAverageUSD 27.41m

Offer

  • Preclinical testing
  • Respiratory gas transport system
  • Blood substitute
  • Nanocapsules for targeted therapy
  • Radioisotopes for diagnosis and treatment
Certifications: GMP

Websites

  • nanogroup.euStrona główna – Nanotechnologia w medycynie – NanoGroup SA
    WordPress 7.1Google AnalyticsGoogle Tag ManagerYoast SEOWPMLNginx

Job offers

The company has its own careers page: nanogroup.eu/kontakt.

Authorized Representatives

Tomasz Adam Ciach age 61 – Management Board Member
Przemysław Daniel Mazurek age 50 – President of the Management Board
Zbigniew Jerzy Posłajko age 56 – Attorney-in-fact (sole)
Piotr Paweł Mierzejewski age 62 – Vice President of the Management Board

Manner of representation

The following persons are authorized to make declarations of will on behalf of the company: in the case of a one-person management board, the President of the Management Board; in the case of a multi-member management board, two members of the management board or a member of the management board jointly with a commercial proxy.

Supervisory board

Jerzy Krzysztof Garlicki age 61 – Supervisory Board Member
Łukasz Ireneusz Gołębiewski age 45 – Supervisory Board Member
Tomasz Hubert Zastawny age 63 – Supervisory Board Member
Jakub Tatak age 51 – Supervisory Board Member
Rafał Płókarz age 56 – Supervisory Board Member

Beneficial owners

Nanogroup is a public company listed on the Warsaw Stock Exchange, so it does not report beneficial owners to the CRBR (Art. 58 of the Polish AML Act). Its shareholders are disclosed in stock-exchange reports.

Subsidiaries

NameStake
Doto Medical sp. z o.o.
100%

Capital group

NameOwnership
Startventure@Poland Sp. z o.o.
6.15%
Grupa Kapitałowa NanoGroup SA
7.17%
41%

Bank accounts

Registered as a VAT taxpayer on 2017-07-20.

Debt

No entries in the National Debtors Register (KRZ).

Public aid

PurposeGross amount
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$4
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$1,282
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$1

Competitors

Change history

DateEvent
2026-03-31Share capital increase
2025-10-14Share capital increase
2025-04-09Share capital increase
2024-12-10Share capital increase
2024-10-10Share capital increase

FAQ

Last updated: 2026-10-07